Future Perspectives in the Treatment of Chronic Lymphocytic Leukemia
Concluding their discussion, Drs Advani, Parrondo, and Chanan-Khan conclude that second-generation BTK inhibitors are the preferred first-line treatment in patients with chronic lymphocytic leukemia due to better efficacy and lower cardiovascular risk, with emerging therapies promising even better outcomes.
EP: 1.Clinical Case Scenario: A 55-Year-Old Patient With Chronic Lymphocytic Leukemia (CLL)
EP: 2.Currently Available Treatment Options for Patients With CLL
EP: 3.The Role of BTKi Monotherapy for CLL
EP: 4.Firstline BTKi Monotherapy in Patients With CLL: 4-Year Follow-Up Data from SEQUOIA
EP: 5.Firstline BTKi Monotherapy in Patients With CLL: 4-Year Follow-Up Data from ELEVATE-TN
EP: 6.Influence of BTKi-Related Adverse Event Patterns on Treatment Selection for Patients With CLLTN
EP: 7.The Role of Combination Venetoclax and BTKi Therapy for Firstline Treatment of CLL
EP: 8.Treatment Approaches in CLL After Disease Progression Following Combination Therapy With Venetoclax and BTKi
EP: 9.Clinical Case Scenario: Managing a Diagnosis of Atrial Fibrillation
EP: 10.Goals of Treatment for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL)
EP: 11.Role of Second-Generation BTKis in R/R CLL: Key Efficacy and Safety Data
EP: 12.Mechanisms of Resistance Observed With Covalent BTKis in CLL
EP: 13.Clinical Case Scenario: Management Strategies for BTKi Intolerance in Patients With CLL
EP: 14.Zanubrutinib in Patients with CLL and Intolerance to Prior BTKIs: Updated Phase 2 Study Data
EP: 15.BTK Inhibitor Treatment Strategies in Chronic Lymphocytic Leukemia
EP: 16.Key Data on Hypertension and Atrial Fibrillation in Patients With CLL
EP: 17.Impact of Treatment Duration on Development of BTKi-Related Atrial Fibrillation in Patients With CLL
EP: 18.Comparing Management of Hypertension versus Atrial Fibrillation in CLL
Now Viewing
EP: 19.Future Perspectives in the Treatment of Chronic Lymphocytic Leukemia
Recent Videos
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
Related Content
